Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 nipocalimab study in pregnancies at risk for severe HDFN
NL-OMON60053Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Erythroblastosis fetalis (HDFN) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Pregnancies without severe fetal or neonatal outcome. Started Apr 2025; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on NL-OMON60053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60053.